Key clinical point: HER2-positive breast cancer patients are more likely to be nonsurgical clinical trial candidates if they have pathologic complete response in both invasive and ductal carcinoma in situ (DCIS) cancer.

Major finding: Neoadjuvant systemic therapy achieved pathologic complete response in 55.4% of invasive cancer cases and 37.5% of both invasive and DCIS cancer cases, while 17.9% of patients had only residual DCIS.

Study details: An analysis of 280 patients with T1-T2, N0-N1 HER2-positive breast cancer who had undergone HER2-targeted therapy, followed by surgical resection and axillary surgery.

Disclosures: Dr. Sun reported no relevant financial disclosures.